Kelly Rauber
Ufficiale delle Risorse Umane presso VERA THERAPEUTICS, INC.
Profilo
Kelly Rauber is currently the Vice President & Head-Human Resources at Vera Therapeutics, Inc. Prior to this, Ms. Rauber held positions as the Senior Director-Human Resources at Dermira, Inc., Orchard Therapeutics Plc, and Oric Pharmaceuticals, Inc. Ms. Rauber completed their undergraduate degree at Santa Clara University.
Posizioni attive di Kelly Rauber
| Società | Posizione | Inizio |
|---|---|---|
| VERA THERAPEUTICS, INC. | Ufficiale delle Risorse Umane | 01/10/2022 |
Precedenti posizioni note di Kelly Rauber
| Società | Posizione | Fine |
|---|---|---|
| DERMIRA, INC. | Ufficiale delle Risorse Umane | - |
| ORCHARD THERAPEUTICS PLC | Ufficiale delle Risorse Umane | - |
| ORIC PHARMACEUTICALS, INC. | Ufficiale delle Risorse Umane | - |
Formazione di Kelly Rauber
| Santa Clara University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ORIC PHARMACEUTICALS, INC. | Health Technology |
| VERA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Kelly Rauber
